Cyclophosphamide in the treatment of focal segmental glomerulosclerosis

Detalhes bibliográficos
Autor(a) principal: Martinelli, Reinaldo Pessôa
Data de Publicação: 2004
Outros Autores: Pereira, Luiz José, Silva, Oriana Maria Mattos e, Okumura, Alice Setsuko, Rocha, Heonir de Jesus Pereira da
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://www.repositorio.ufba.br/ri/handle/ri/4801
Resumo: p.1365-1372
id UFBA-2_dceaa447eaec308f07e15c392b84bc81
oai_identifier_str oai:repositorio.ufba.br:ri/4801
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Martinelli, Reinaldo PessôaPereira, Luiz JoséSilva, Oriana Maria Mattos eOkumura, Alice SetsukoRocha, Heonir de Jesus Pereira daMartinelli, Reinaldo PessôaPereira, Luiz JoséSilva, Oriana Maria Mattos eOkumura, Alice SetsukoRocha, Heonir de Jesus Pereira da2011-12-12T12:18:30Z2011-12-12T12:18:30Z20041678-4510http://www.repositorio.ufba.br/ri/handle/ri/480137(9)p.1365-1372Prednisone is the initial treatment of primary focal segmental glomerulosclerosis. However, when immunosuppressive agents in combination with steroids are used in the treatment of prednisone-dependent and prednisone-resistant patients the remission rate is variable. We report a long-term trial using cyclophosphamide (2.0 to 3.0 mg/kg body weight for 12 weeks) in combination with prednisone (1.0 to 2.0 mg/kg body weight), as compared with prednisone alone for the treatment of prednisone-resistant and frequently relapsing nephrotic syndrome and focal segmental glomerulosclerosis. Fifty-four patients (34 males and 20 females) with a diagnosis of idiopathic nephrotic syndrome and focal segmental glomerulosclerosis, followed-up for an average of 86.1 ± 82.4 months, were evaluated. Complete remission occurred in 20.4% and partial remission in 14.8% of the patients treated with steroids and in 26.7 and 20.0% of the patients treated with cyclophosphamide + prednisone, respectively. Of the 24 prednisoneresistant patients treated with steroids in combination with cyclophosphamide, 33.3% obtained a complete/partial response. At the time of final evaluation, 25% of the patients treated with prednisone and 10.0% of those treated with prednisone in combination with cyclophosphamide had reached end-stage renal disease. Persistent nephrotic syndrome and progressive renal insufficiency were more frequently observed among the patients treated with prednisone alone (50.0 vs 33.3% and 33.3 vs 16.7%, respectively). The treatments were well tolerated and no patient experienced adverse reactions requiring discontinuation of medications. Although open-label and non-randomized, the present trial showed that cyclophosphamide is a reasonable choice for the treatment of primary focal segmental glomerulosclerosis and prednisone-resistant nephrotic syndrome.Submitted by Ana Valéria de Jesus Moura (anavaleria_131@hotmail.com) on 2011-12-12T12:18:30Z No. of bitstreams: 1 4393.pdf: 516784 bytes, checksum: a882bf61fb5e7f2ec45963b67d858ae1 (MD5)Made available in DSpace on 2011-12-12T12:18:30Z (GMT). No. of bitstreams: 1 4393.pdf: 516784 bytes, checksum: a882bf61fb5e7f2ec45963b67d858ae1 (MD5) Previous issue date: 2004PrednisoneNephrotic syndromeCyclophosphamidePrimary glomerular diseaseFocal segmentalglomerulosclerosisCyclophosphamide in the treatment of focal segmental glomerulosclerosisBrazilian Journal of Medical and Biological Researchinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleengreponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAinfo:eu-repo/semantics/openAccessLICENSElicense.txtlicense.txttext/plain1748https://repositorio.ufba.br/bitstream/ri/4801/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52ORIGINAL4393.pdf4393.pdfapplication/pdf516784https://repositorio.ufba.br/bitstream/ri/4801/1/4393.pdfa882bf61fb5e7f2ec45963b67d858ae1MD51TEXT4393.pdf.txt4393.pdf.txtExtracted texttext/plain30397https://repositorio.ufba.br/bitstream/ri/4801/3/4393.pdf.txt4cf430cb8c16a2647f7696775e95b6cbMD53ri/48012022-07-05 14:03:16.885oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:03:16Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Cyclophosphamide in the treatment of focal segmental glomerulosclerosis
dc.title.alternative.pt_BR.fl_str_mv Brazilian Journal of Medical and Biological Research
title Cyclophosphamide in the treatment of focal segmental glomerulosclerosis
spellingShingle Cyclophosphamide in the treatment of focal segmental glomerulosclerosis
Martinelli, Reinaldo Pessôa
Prednisone
Nephrotic syndrome
Cyclophosphamide
Primary glomerular disease
Focal segmental
glomerulosclerosis
title_short Cyclophosphamide in the treatment of focal segmental glomerulosclerosis
title_full Cyclophosphamide in the treatment of focal segmental glomerulosclerosis
title_fullStr Cyclophosphamide in the treatment of focal segmental glomerulosclerosis
title_full_unstemmed Cyclophosphamide in the treatment of focal segmental glomerulosclerosis
title_sort Cyclophosphamide in the treatment of focal segmental glomerulosclerosis
author Martinelli, Reinaldo Pessôa
author_facet Martinelli, Reinaldo Pessôa
Pereira, Luiz José
Silva, Oriana Maria Mattos e
Okumura, Alice Setsuko
Rocha, Heonir de Jesus Pereira da
author_role author
author2 Pereira, Luiz José
Silva, Oriana Maria Mattos e
Okumura, Alice Setsuko
Rocha, Heonir de Jesus Pereira da
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Martinelli, Reinaldo Pessôa
Pereira, Luiz José
Silva, Oriana Maria Mattos e
Okumura, Alice Setsuko
Rocha, Heonir de Jesus Pereira da
Martinelli, Reinaldo Pessôa
Pereira, Luiz José
Silva, Oriana Maria Mattos e
Okumura, Alice Setsuko
Rocha, Heonir de Jesus Pereira da
dc.subject.por.fl_str_mv Prednisone
Nephrotic syndrome
Cyclophosphamide
Primary glomerular disease
Focal segmental
glomerulosclerosis
topic Prednisone
Nephrotic syndrome
Cyclophosphamide
Primary glomerular disease
Focal segmental
glomerulosclerosis
description p.1365-1372
publishDate 2004
dc.date.issued.fl_str_mv 2004
dc.date.accessioned.fl_str_mv 2011-12-12T12:18:30Z
dc.date.available.fl_str_mv 2011-12-12T12:18:30Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.repositorio.ufba.br/ri/handle/ri/4801
dc.identifier.issn.none.fl_str_mv 1678-4510
dc.identifier.number.pt_BR.fl_str_mv 37(9)
identifier_str_mv 1678-4510
37(9)
url http://www.repositorio.ufba.br/ri/handle/ri/4801
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/4801/2/license.txt
https://repositorio.ufba.br/bitstream/ri/4801/1/4393.pdf
https://repositorio.ufba.br/bitstream/ri/4801/3/4393.pdf.txt
bitstream.checksum.fl_str_mv 8a4605be74aa9ea9d79846c1fba20a33
a882bf61fb5e7f2ec45963b67d858ae1
4cf430cb8c16a2647f7696775e95b6cb
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1801502435265478656

Registros relacionados